Your psychiatrist just recommended transcranial magnetic stimulation (TMS) for your treatment-resistant depression. You've read about the results, seen the FDA clearances, and you're ready to try it. Then comes the question that determines whether this happens at all: is TMS covered by insurance?
The short answer is yes, most major insurers cover TMS for treatment-resistant depression. But the real answer is more complicated. Coverage depends on your specific payer, your diagnosis, how many medications you've already tried, and whether your provider submits the prior authorization correctly the first time. First-submission denial rates run 30-50% across most commercial payers, even when patients clearly meet medical necessity criteria.
This article gives you the honest breakdown: which insurers cover TMS and under exactly what conditions, what the prior authorization process actually requires, why denials are common and how to appeal them, and what you'll pay out of pocket when coverage succeeds or fails. If you're a provider evaluating TMS as a service line, this also covers the billing infrastructure and reimbursement rates you need to know before investing in equipment.
Which Major Insurers Cover TMS in 2026
Medicare, Medicaid (state-dependent), UnitedHealthcare, Cigna, Aetna, Blue Cross Blue Shield, and Humana all provide coverage for TMS when used to treat major depressive disorder (MDD) that has not responded to prior antidepressant trials. This represents the vast majority of commercially insured patients in the United States.
Medicare covers TMS under Part B for treatment-resistant depression. The coverage decision came in 2011 and requires documentation of failure to achieve satisfactory improvement from at least one antidepressant medication trial of adequate dose and duration in the current episode. Medicare reimburses around $280-$320 per session depending on geographic locality, making it one of the more predictable payers for TMS services.
Medicaid coverage varies dramatically by state. Some states like California, New York, and Massachusetts provide robust TMS coverage with criteria similar to Medicare. Other states either exclude TMS entirely or require such restrictive prior authorization criteria that approvals are rare. Providers billing Medicaid for TMS should verify state-specific coverage policies before initiating treatment.
Commercial payers (UnitedHealthcare, Cigna, Aetna, BCBS plans, Humana) generally cover TMS for treatment-resistant depression but require more extensive documentation than Medicare. Expect requirements for 2-4 failed medication trials, formal depression severity scores, and detailed treatment history. Reimbursement rates range from $250-$400 per session depending on the payer and your contracted rates.
Coverage for conditions beyond major depression is far more limited. OCD has FDA clearance for deep TMS (Brainsway system) as of 2018, and some commercial payers now cover it, but many still consider it investigational. PTSD, anxiety disorders, and substance use disorders remain largely uncovered by insurance even where emerging evidence supports TMS use. If your diagnosis is anything other than treatment-resistant depression, expect a much harder path to coverage approval.
Standard TMS Insurance Coverage Requirements and Prior Authorization
Nearly every insurer requires prior authorization before approving TMS treatment. The prior auth process involves submitting clinical documentation that proves the patient meets medical necessity criteria. Here's what most payers require:
Documented failure of multiple antidepressant trials. Most commercial insurers require 2-4 antidepressant medication trials at therapeutic doses for adequate duration (typically 6-8 weeks minimum) without satisfactory response. The medications must come from different classes. Some payers also require documentation of psychotherapy attempts.
Formal depression severity measurement. A PHQ-9 score of 15 or higher is the typical threshold, though some payers accept other validated instruments like the Hamilton Depression Rating Scale (HAM-D). The score must be current, usually within the past two weeks.
Psychiatrist letter of medical necessity. This letter should detail the patient's treatment history, current symptoms, functional impairment, why previous treatments failed, and why TMS is clinically appropriate now. Generic templates get denied. Specific, patient-centered narratives that document the severity and persistence of symptoms win approvals.
Exclusion of contraindications. Insurers want confirmation that the patient has no metallic implants near the treatment site, no history of seizures, and no other medical contraindications to magnetic stimulation. This usually requires a brief medical screening form.
The prior authorization process typically takes 5-14 business days for a decision, though some payers respond within 72 hours. Urgent or expedited reviews are possible when clinical circumstances warrant faster decisions. Similar to intensive outpatient program reimbursement, TMS authorization requires detailed clinical documentation that clearly establishes medical necessity.
Why First TMS Prior Authorization Denials Are Common
Here's what most TMS clinics won't tell you upfront: 30-50% of first-submission prior authorizations get denied, even for patients who clearly meet coverage criteria. This happens for predictable reasons that have nothing to do with whether TMS is medically appropriate for you.
Incomplete medication trial documentation. The most common denial reason is insufficient proof that prior antidepressant trials were adequate. If your psychiatrist's notes don't explicitly document the medication name, dose, duration, and reason for discontinuation, the payer will deny for lack of evidence. Saying "patient failed multiple SSRIs" without specifics guarantees a denial.
Missing depression severity scores. If your chart doesn't include a recent PHQ-9 or HAM-D score, expect a denial. Payers want objective measurement, not just clinical impression. A statement that the patient is "severely depressed" doesn't meet the standard.
Wrong diagnosis codes. TMS is covered for major depressive disorder (F33.2, F33.3 for recurrent severe depression). If the claim uses a different depression code or includes comorbid diagnoses that confuse the primary indication, denials follow. Accurate behavioral health billing codes matter enormously in prior authorization approvals.
Payer policy changes without provider notification. Insurance companies regularly update their TMS coverage policies, adding new requirements or changing the number of required medication failures. Providers working from outdated policy documents submit authorizations that no longer meet current criteria.
The good news: most denials are overturned on appeal when the provider submits the missing documentation. The bad news: appeals add 2-4 weeks to the process, delaying treatment for patients who are already suffering.
How to Appeal a Denied TMS Prior Authorization
If your initial TMS prior authorization gets denied, don't assume coverage is impossible. The appeal process exists specifically because first denials are often based on incomplete information rather than true lack of medical necessity.
Request the specific denial reason in writing. Insurance companies must provide a written explanation of why they denied coverage. This letter will cite the exact policy criteria you allegedly didn't meet. Read it carefully. Often the denial points to a simple documentation gap that's easy to fix.
Gather the missing documentation. If the denial cites insufficient proof of medication trials, pull pharmacy records showing filled prescriptions and dates. If it questions depression severity, administer and document a current PHQ-9. If it asks for more detail on functional impairment, have your psychiatrist write a supplemental letter with specific examples of how depression affects your work, relationships, and daily functioning.
Invoke mental health parity laws. The Mental Health Parity and Addiction Equity Act (MHPAEA) requires insurers to cover mental health treatments, including TMS for depression, with the same standards they apply to medical/surgical treatments. If your insurer covers other outpatient procedures for chronic conditions without requiring 4 failed treatments first, they may be violating parity by imposing stricter standards on TMS. Cite parity explicitly in your appeal letter.
Request a peer-to-peer review. Most insurers allow the treating psychiatrist to speak directly with the insurance company's medical reviewer (usually also a psychiatrist) to discuss the case. These conversations often resolve denials when the treating provider can explain nuances that didn't come through in written documentation. Request this option early in the appeal process.
Escalate to external review if necessary. If internal appeals fail, you have the right to request an independent external review by a third-party medical reviewer not employed by your insurance company. External reviews overturn insurer denials in about 40% of cases. Your state insurance department can provide information on how to request external review.
Appeal timelines matter. Most insurers require appeals within 60-180 days of the denial notice. Don't wait. Start the appeal process immediately while the clinical documentation is still current.
Deep TMS vs. Standard TMS: Coverage Differences That Matter
Not all TMS systems are the same, and insurers don't cover them all equally. Understanding the difference between standard TMS and deep TMS (dTMS) affects both your treatment options and your coverage likelihood.
Standard TMS uses a figure-8 coil positioned over the dorsolateral prefrontal cortex. It stimulates brain tissue to a depth of about 1.5-2 cm. This is the original TMS technology, FDA-cleared for depression in 2008, and it's what most insurance policies reference when they describe TMS coverage criteria.
Deep TMS (dTMS) uses an H-coil that stimulates deeper and broader brain regions, reaching up to 4-5 cm depth. Brainsway manufactures the primary FDA-cleared deep TMS system. It received FDA clearance for depression in 2013 and for OCD in 2018. The deeper stimulation theoretically allows treatment of conditions involving brain circuits that standard TMS can't reach effectively.
Here's why this matters for insurance: dTMS for OCD has better coverage than standard TMS for OCD because Brainsway's device holds the specific FDA clearance. If you're seeking TMS for obsessive-compulsive disorder, choosing a provider with a Brainsway system may significantly improve your coverage odds. Several major commercial payers now cover dTMS for OCD while still considering standard TMS for OCD investigational.
For depression treatment, most insurers cover both standard TMS and dTMS under the same criteria. Some payers reimburse them at identical rates. Others pay slightly more for dTMS sessions, reflecting the different CPT code (90867 for standard TMS, 90868 for dTMS). Check your specific plan's policy documents or call the number on your insurance card to confirm whether device type affects your coverage.
Theta Burst Stimulation (TBS) Coverage: The Faster Protocol Insurers Are Still Learning
Theta burst stimulation (TBS) is a newer TMS protocol that delivers a full treatment session in 3 minutes instead of the standard 37-minute session. The FDA cleared TBS as equivalent to standard TMS in 2018 based on clinical trials showing comparable efficacy and safety.
For patients, TBS offers obvious advantages: shorter sessions mean less time away from work, easier scheduling, and reduced burden on caregivers who provide transportation. For providers, TBS allows higher patient throughput with the same equipment investment.
But insurance coverage for TBS lags behind the clinical evidence. Many commercial payers still require standard TMS protocols unless their policy explicitly includes TBS. Some insurers cover TBS but reimburse it at a lower rate than standard TMS, arguing that the shorter session time justifies reduced payment (despite identical clinical outcomes and FDA equivalence).
Medicare covers TBS using the same CPT codes and reimbursement rates as standard TMS, which has helped drive broader commercial payer acceptance. UnitedHealthcare, Aetna, and several BCBS plans now explicitly include TBS in their TMS coverage policies. Cigna and Humana coverage varies by plan.
If you're considering TBS, verify coverage before starting treatment. Ask your TMS provider to confirm that your specific insurance plan covers theta burst stimulation, not just standard TMS. The prior authorization should explicitly mention TBS if that's the protocol you'll receive. Surprises after treatment starts can leave you responsible for thousands in unexpected costs.
What Patients Actually Pay Out of Pocket for TMS
Even when insurance covers TMS, you'll likely have out-of-pocket costs. Here's what to expect in different coverage scenarios.
When insurance approves and covers TMS: Your cost-sharing depends on your plan's deductible, copay, and coinsurance structure. Most patients pay between $500 and $2,000 total for a complete TMS course after meeting their deductible. If you haven't met your annual deductible yet, expect to pay the full contracted rate (typically $250-$400 per session) until you hit that threshold, then copays or coinsurance for remaining sessions.
A standard TMS course involves 36 sessions over 6-9 weeks, plus possible taper sessions. At $300 per session, that's $10,800 total billed to insurance. With a typical 80/20 coinsurance after deductible, you might pay your $2,000 deductible plus 20% of the remaining $8,800, totaling roughly $3,760. But most plans have an out-of-pocket maximum that caps your annual cost-sharing, often around $3,000-$8,000 depending on plan tier.
When insurance denies coverage: Cash-pay costs for TMS range from $6,000 to $15,000 for a full 36-session protocol, depending on the provider and geographic market. Urban markets and hospital-based TMS programs typically charge more than standalone TMS clinics. Some providers offer payment plans or financing options to spread costs over 12-24 months.
Maintenance TMS sessions: After the initial treatment course, some patients need periodic maintenance sessions to sustain results. Insurance coverage for maintenance TMS is inconsistent. Some payers approve ongoing sessions monthly or quarterly if the patient demonstrates initial response and then shows symptom return. Others deny maintenance sessions entirely, requiring patients to pay cash (typically $250-$400 per session).
Before starting TMS, get a detailed cost estimate from your provider that includes your specific insurance plan's coverage terms, your current deductible status, and your out-of-pocket maximum. Don't rely on general estimates. Your financial responsibility can vary by thousands of dollars depending on plan details and timing within your benefit year.
What Behavioral Health Operators Need to Know About Billing TMS
If you're a behavioral health practice considering adding TMS services, understand that TMS billing requires infrastructure most general outpatient practices don't have. The reimbursement is substantial, but so are the operational complexities.
CPT codes for TMS: The primary codes are 90867 (initial motor threshold determination and delivery), 90868 (subsequent motor threshold re-determination with delivery), and 90869 (subsequent delivery only). Most sessions bill 90869. Motor threshold testing (90867, 90868) happens at the start of treatment and periodically throughout the course. These codes reimburse significantly higher than standard psychotherapy codes, typically $280-$400 per session depending on payer and geography.
Credentialing and contracting: Not all behavioral health provider contracts include TMS reimbursement. You may need to renegotiate contracts or submit new credentialing applications specifically for TMS services. Some payers credential TMS separately from other behavioral health services, requiring additional paperwork and waiting periods before you can bill. This process can take 60-120 days, so start it before purchasing equipment.
Prior authorization infrastructure: Successful TMS programs have dedicated staff who handle prior authorizations, appeals, and insurance follow-up. The authorization process is too complex and time-intensive to add onto an existing biller's workload without dedicated training. Budget for at least 0.5 FTE focused on TMS authorizations if you're treating 5-10 new TMS patients monthly. Much like billing for group health behavior assessments, TMS requires specific documentation and coding expertise.
Common denial patterns to anticipate: Expect higher denial rates in your first 6-12 months of offering TMS as your team learns payer-specific requirements. Track denial reasons systematically and adjust your documentation templates accordingly. The most successful TMS programs maintain denial rates under 20% after the initial learning curve by using payer-specific authorization checklists and pre-submission chart audits.
Equipment and space requirements: TMS equipment costs $100,000-$150,000 for a standard system, plus annual service contracts around $15,000-$20,000. You need a dedicated treatment room (roughly 10x10 feet minimum) with stable electrical supply and space for the TMS chair, equipment, and clinician workstation. The room should be quiet, private, and comfortable since patients spend 20-40 minutes per session. These infrastructure needs differ significantly from typical outpatient behavioral health spaces, similar to the facility considerations when you're planning to open a specialized treatment center.
Reimbursement rates by payer: Medicare pays approximately $280-$320 per session depending on locality. Commercial payers range from $250-$400 per session. Medicaid rates (in states that cover TMS) typically fall between $180-$280 per session. A full 36-session course generates $10,000-$14,000 in revenue at commercial rates, making TMS one of the higher-reimbursing behavioral health services when you achieve consistent authorizations and collections.
Break-even analysis: Most TMS programs need to treat 8-12 patients monthly to cover equipment costs, staff time, and overhead. Programs treating 15-20 patients monthly typically generate $150,000-$250,000 in annual net revenue after expenses. The model works best when integrated into an existing psychiatric practice that can generate TMS referrals internally rather than relying entirely on external marketing and referrals.
State-Specific Medicaid Coverage Variations
Medicaid TMS coverage varies so dramatically by state that it deserves specific attention. If you're a Medicaid beneficiary considering TMS, your state determines whether coverage exists at all.
States with robust TMS coverage: California, New York, Massachusetts, Oregon, and Washington provide Medicaid coverage for TMS with criteria similar to Medicare (documented failure of at least one antidepressant trial). These states recognize TMS as an evidence-based treatment for medication-resistant depression and include it in their Medicaid formularies.
States with limited or no coverage: Many Southern and rural states either exclude TMS from Medicaid coverage entirely or impose such restrictive criteria that approvals are extremely rare. Texas, Florida, and several other large Medicaid states have inconsistent coverage that varies by managed care plan.
Managed Medicaid plans: In states that use managed care organizations (MCOs) to administer Medicaid benefits, TMS coverage often depends on which MCO manages your benefits. One MCO in the same state might cover TMS while another denies it as investigational. This creates confusing scenarios where two Medicaid patients in the same state have completely different coverage based solely on their assigned MCO.
If you're on Medicaid and considering TMS, call your plan's member services line and ask specifically: "Does my plan cover transcranial magnetic stimulation for treatment-resistant depression?" Request the coverage policy in writing. Don't start treatment based on verbal assurances alone. Similar to navigating state-specific licensing and reimbursement requirements, Medicaid TMS coverage requires understanding your specific state's policies.
The Bottom Line: Is TMS Covered by Insurance for You?
Yes, TMS is covered by insurance for treatment-resistant depression under most major payers, including Medicare and commercial plans. But coverage approval requires meeting specific criteria, submitting thorough documentation, and often appealing initial denials. The process takes time, patience, and a provider who knows how to navigate payer requirements.
If you have treatment-resistant depression and have tried multiple medications without success, you likely qualify for TMS coverage. Expect to provide detailed treatment history, current depression severity scores, and a clear explanation of why previous treatments failed. Work with a TMS provider experienced in insurance authorizations, not one that primarily operates on a cash-pay model.
For conditions beyond major depression, coverage becomes much harder. OCD may be covered if you're seeking deep TMS with the Brainsway system. PTSD, anxiety, and addiction indications remain largely uncovered despite emerging evidence. If your diagnosis isn't treatment-resistant depression, prepare for a significant chance of denial and potential out-of-pocket costs of $6,000-$15,000.
The coverage landscape continues to evolve. More payers are adding TMS coverage as evidence accumulates and costs decline. But as of 2026, the honest answer is that TMS coverage exists, requires work to obtain, and depends heavily on your specific diagnosis, payer, and provider's authorization expertise.
Get Help Understanding Your TMS Coverage Options
Navigating TMS insurance coverage shouldn't prevent you from accessing a treatment that could significantly improve your depression. If you're struggling to understand whether your insurance will cover TMS, what the prior authorization process requires, or what your out-of-pocket costs will be, reach out for guidance.
For patients: Contact TMS providers in your area and ask about their insurance authorization success rates with your specific payer. The best programs offer benefits verification before you commit to treatment, giving you a clear picture of coverage and costs upfront.
For providers: If you're evaluating TMS as a service line addition and need to understand the reimbursement landscape, credentialing requirements, and billing infrastructure necessary for success, specialized consulting can help you avoid expensive mistakes. Understanding behavioral health reimbursement complexities, from neurobehavioral assessment billing to TMS authorization strategies, makes the difference between a profitable service line and a costly operational burden.
TMS works for many patients with treatment-resistant depression. Don't let insurance confusion stop you from exploring whether it's right for you. Get the facts, understand your coverage, and make an informed decision about your next treatment step.
